Stocks Comparison
American Vanguard vs Bioceres Crop Solutions: revenue, profit, margins and growth compared
American Vanguard brought in $515.1M of revenue in fiscal 2025, Bioceres Crop Solutions $335.1M in fiscal 2025. Revenue changed by -5.9% at American Vanguard and -27.9% at Bioceres Crop Solutions on the year before, so American Vanguard grew faster. American Vanguard kept -9.7% of its revenue as net profit, Bioceres Crop Solutions -16.5%. Free cash flow was -$25.1M at American Vanguard and $44.3M at Bioceres Crop Solutions.
Side by side, latest fiscal year
| AVD | BIOX | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (June 30, 2025) |
| Revenue | $515.1M | $335.1M |
| Revenue growth | -5.9% | -27.9% |
| Net income | -$49.9M | -$55.4M |
| Net margin | -9.7% | -16.5% |
| Free cash flow | -$25.1M | $44.3M |
| Free cash flow margin | -4.9% | 13.2% |
| Earnings per share (diluted) | -$1.75 | -$0.88 |
| Cash | $12.4M | $32.7M |
| Debt | $174M | n/a |
| Price to earnings | n/a | n/a |
| Market value | $24.1M | $13.6M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #331 of 603 · Industrials | #361 of 603 · Industrials |
Over the years
Questions about American Vanguard and Bioceres Crop Solutions
Which is bigger by revenue, American Vanguard or Bioceres Crop Solutions?
American Vanguard is bigger by revenue: $515.1M in fiscal 2025, against $335.1M for Bioceres Crop Solutions in fiscal 2025.
Which keeps more of its revenue as profit, American Vanguard or Bioceres Crop Solutions?
American Vanguard had a net margin of -9.7% in fiscal 2025; Bioceres Crop Solutions had -16.5% in fiscal 2025.
Which grew revenue faster, American Vanguard or Bioceres Crop Solutions?
In their latest fiscal years revenue changed by -5.9% at American Vanguard and -27.9% at Bioceres Crop Solutions.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.